Factbox: Pending US vaccine decisions as Kennedy takes top health job

Bavarian Nordic A/S

13/02/2025 19:09

Feb 13 (Reuters) - Robert F. Kennedy Jr, a vaccine
critic who has pledged to tackle chronic disease, was confirmed
by the U.S. Senate as Health Secretary on Thursday, after
overcoming resistance from the medical establishment and members
of Congress with promises to limit his role in vaccine policy.
    As head of the health department, which oversees more than
$3 trillion in healthcare spending, Kennedy would have authority
over agencies including the U.S. Food and Drug Administration
(FDA) and the Centers for Disease Control and Prevention (CDC).
    Here are some pending regulatory decisions and meetings on
vaccines coming up over the next few months:  
    
  EXPECTED          REGULATORY EVENT              COMPANY
    DATE                                     
   Feb 14      FDA decision on company's     GSK plc   GSK.L  
              5-in-1 meningococcal vaccine   
                       candidate             
   Feb 14      FDA decision on company's      Bavarian Nordic
             chikungunya vaccine, Vimkunya,       BAVA.CO  
              in individuals 12 years and    
                        older                
   Feb 26     CDC's Advisory Committee on    GSK plc   GSK.L  
             Immunization Practices (ACIP)   
             to vote on GSK's meningococcal  
                       vaccine               
   Feb 26        CDC's ACIP to vote on        AstraZeneca  
   Feb 27        CDC's ACIP to vote on       GSK plc   GSK.L  
                 company's Respiratory       
               Syncytial Virus vaccine in    
                  high-risk adults 18-       
                      49 years old           
   Feb 27        CDC's ACIP to vote on       Moderna  MRNA.O  
                 company's Respiratory       
                Syncytial Virus vaccine,     
              mRESVIA, in high-risk adults   
                   18 to 59 years old        
   April     FDA decision on Emergency Use   Novavax  NVAX.O  
               Authorization of company's    
               2024-2025 formula COVID-19    
                 vaccine (NVX-CoV2705)       
   May 31      FDA decision on company's     Moderna  MRNA.O  
                next-generation COVID-19     
                  vaccine (mRNA-1283)        
  June 10       FDA decision on company's      Merck  MRK.N  
              monoclonal antibody designed   
              to protect infants from RSV    
                        disease              
 

 (Reporting by Mariam Sunny in Bengaluru; Editing by Anil
D'Silva)
 ((Mariam.ESunny@thomsonreuters.com;))